Apo-1/Fas (CD95) Gene Polymorphism in Korean Hepatocellular Carcinoma Patients.
- Author:
Sung Soo KIM
1
;
Seung Jae HONG
;
Yun Gul AHN
;
Bong Seog KIM
;
Young Jin YUH
;
Kye Young HAN
;
Hee Jae LEE
;
Joo Ho CHUNG
;
Sung Vin YIM
;
Jaeyoung CHO
;
Yeon Hee PARK
Author Information
1. Department of Pharmacology, College of Medicine, Kangwon National University, Kangwon-do 200-701, Korea. ysvin@kangwon.ac.kr
- Publication Type:Original Article
- Keywords:
Hepatocellular carcinoma;
Apo-1/Fas (CD95);
Polymorphism;
PCR-RFLP;
Apoptosis
- MeSH:
Apoptosis;
Carcinoma, Hepatocellular*;
Cell Death;
Fas Ligand Protein;
Genotype;
Humans;
Polymorphism, Restriction Fragment Length
- From:The Korean Journal of Physiology and Pharmacology
2003;7(1):29-31
- CountryRepublic of Korea
- Language:English
-
Abstract:
It is well known that different expression of Apo-1/Fas (CD95) plays important roles in various tumors and hepatocellular carcinoma (HCC) pathogenesis. Apo-1/Fas mediated apoptosis is one of the important pathways of apoptosis and is known to mediate apoptotic cell death by fas ligand (FasL). To examine the possible relationship between Apo-1/Fas gene polymorphism and HCC susceptibility, MvaI restriction fragment length polymorphism (RFLP) of Apo-1/Fas gene was examined in 94 Korean HCC patients and 240 control subjects. No statistically significant difference in the genotypic distribution and allelic frequencies was found between the control and the HCC. It is, therefore, concluded that Apo-1/Fas gene polymorphism is not associated with HCC susceptibility. Further studies are needed in order to clarify the relationships between genotypes of Apo-1/Fas gene and HCC pathogenesis.
